 |
(Photo= Yonhap news) |
[Alpha Biz= Reporter Kim Jisun] Celltrion's autoimmune disease treatment, 'ZYMFENTRA,' has been included in the formulary of all three major U.S. Pharmacy Benefit Managers (PBMs).
On August 5, Celltrion announced on its website that it successfully completed listing agreements with one of the top three PBMs for ZYMFENTRA as of August 2. This means that ZYMFENTRA is now listed with CVS Health, Express Scripts (ESI), and Optum, covering the major PBMs in the U.S.
PBMs in the U.S. specialize in managing prescription drugs, working with insurers to handle drug lists, negotiate prices, and build pharmacy networks. Being listed in these PBM formularies indicates inclusion in the U.S. healthcare insurance system. The three major PBMs—CVS Health, Express Scripts, and Optum—control about 80% of the U.S. insurance market.
Celltrion has completed insurance agreements with Express Scripts and one other PBM, covering both private and public insurance. Agreements with the remaining PBM are pending for private insurance, having already been secured for public insurance. This strategic move allows Celltrion to secure approximately 75% coverage of the U.S. insurance market within five months of ZYMFENTRA's launch in March.
AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)
